| Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors P Pinzani, V D’Argenio, M Del Re, C Pellegrini, F Cucchiara, F Salvianti, ... Clinical Chemistry and Laboratory Medicine (CCLM) 59 (7), 1181-1200, 2021 | 87 | 2021 |
| Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide M Del Re, V Conteduca, S Crucitta, G Gurioli, C Casadei, G Restante, ... Prostate cancer and prostatic diseases 24 (2), 524-531, 2021 | 38 | 2021 |
| Understanding EGFR heterogeneity in lung cancer A Passaro, U Malapelle, M Del Re, I Attili, A Russo, E Guerini-Rocco, ... ESMO open 5 (5), e000919, 2020 | 38 | 2020 |
| A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC M Del Re, F Cucchiara, E Rofi, L Fontanelli, I Petrini, N Gri, G Pasquini, ... Cancer Immunology, Immunotherapy 70, 1667-1678, 2021 | 32 | 2021 |
| PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients M Del Re, S Crucitta, G Lorenzini, C De Angelis, L Diodati, D Cavallero, ... Pharmacological Research 163, 105241, 2021 | 32 | 2021 |
| Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours S Crucitta, F Cucchiara, R Mathijssen, J Mateo, A Jager, A Joosse, ... Cancer Treatment Reviews 104, 102340, 2022 | 27 | 2022 |
| Integrating liquid biopsy and radiomics to monitor clonal heterogeneity of EGFR-positive non-small cell lung cancer F Cucchiara, M Del Re, S Valleggi, C Romei, I Petrini, M Lucchesi, ... Frontiers in oncology 10, 593831, 2020 | 26 | 2020 |
| erbB in NSCLC as a molecular target: current evidences and future directions M Del Re, F Cucchiara, I Petrini, S Fogli, A Passaro, S Crucitta, I Attili, ... ESMO open 5 (4), e000724, 2020 | 24 | 2020 |
| Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours? F Cucchiara, F Pasqualetti, FS Giorgi, R Danesi, G Bocci Pharmacological Research 156, 104786, 2020 | 22 | 2020 |
| Multicenter study on sleep and circadian alterations as objective markers of mild cognitive impairment and Alzheimer’s disease reveals sex differences B Guarnieri, M Maestri, F Cucchiara, A Lo Gerfo, A Schirru, D Arnaldi, ... Journal of Alzheimer's Disease 78 (4), 1707-1719, 2020 | 21 | 2020 |
| Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors M Del Re, RHN van Schaik, S Fogli, RHJ Mathijssen, F Cucchiara, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1875 (1), 188463, 2021 | 19 | 2021 |
| Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives F Cucchiara, I Petrini, C Romei, S Crucitta, M Lucchesi, S Valleggi, ... Pharmacological Research 169, 105643, 2021 | 17 | 2021 |
| Precision medicine in lymphoma by innovative instrumental platforms A Di Paolo, E Arrigoni, G Luci, F Cucchiara, R Danesi, S Galimberti Frontiers in oncology 9, 1417, 2019 | 17 | 2019 |
| Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or … C Vivaldi, S Crucitta, S Catanese, F Cucchiara, E Arrigoni, I Pecora, E Rofi, ... The Pharmacogenomics Journal 21 (2), 233-242, 2021 | 15 | 2021 |
| Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics T Di Desidero, P Orlandi, A Fioravanti, G Alì, C Cremolini, F Loupakis, ... Biochemical Pharmacology 164, 94-105, 2019 | 15 | 2019 |
| A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry G Luci, F Cucchiara, L Ciofi, M Lastella, R Danesi, A Di Paolo Journal of Pharmaceutical and Biomedical Analysis 182, 113132, 2020 | 14 | 2020 |
| CYP17A1 polymorphism c.-362T> C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone S Crucitta, M Del Re, F Paolieri, F Bloise, A Sbrana, E Sammarco, ... Cancer Chemotherapy and Pharmacology 86, 527-533, 2020 | 13 | 2020 |
| Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data F Cucchiara, S Ferraro, G Luci, G Bocci Pharmacological Research 175, 105976, 2022 | 12 | 2022 |
| Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer S Fogli, G Gianfilippo, F Cucchiara, M Del Re, L Valerio, R Elisei, ... Critical Reviews in Oncology/Hematology 163, 103366, 2021 | 11 | 2021 |
| Electrophysiological features of sleep in children with Kir4. 1 channel mutations and Autism–Epilepsy phenotype: a preliminary study F Cucchiara, P Frumento, T Banfi, G Sesso, M Di Galante, P d’Ascanio, ... Sleep 43 (4), zsz255, 2020 | 9 | 2020 |
Romano DanesiProfessor of Pharmacology, University of MilanoVerified email at unimi.it
